**Impact of preoperative risk factors on outcome after gastrectomy**

Corresponding author

Ann-Kathrin Eichelmann

Department of General, Visceral and Transplant Surgery

University Hospital Münster, Albert-Schweitzer-Campus 1, W1

48149 Münster, Germany

Ann-Kathrin.Eichelmann@ukmuenster.de

**Additional file 1** Cologne Risk Score [[17](#_ENREF_17)]

|  |  |  |
| --- | --- | --- |
| **Variable** | **Classification of pathologic finding** |  |
| **1 point****(normal risk)** | **2 points****(intermediate risk)** | **3 points****(high risk)** |
| **Pulmonary function**VCFEV1 | > 90%>80% | 70-90%60-80% | < 70%< 60% | x 2 |
| **Cardiovascular function**ECGMyocardial infarction (date, number) Blood pressure (BP) | NormalNo | CHD, PAD II-IVAbnormal> 6 months> 145/95 mmHg | Heart failure NYHA III - IV< 6 months, > 1 Systolic BP > 180 mmHg | x 3 |
| **Renal function**Urea (mg/dl)Creatinine (mg/dl)Creatinine-clearance  | < 50 < 1,1 95 - 160 | > 50> 1,2< 94 |  | x 1 |
| **Hepatic function** | Child A | Child B | Child C | x 2 |
| **Endocrine function** | Blood glucose level55 - 115 mg% | Insulin-dependent diabetes mellitus |  | x 1 |
| **General status**BMI (kg/m²)Karnofsky indexWeight loss**Alcohol consumption****Tobacco consumption** (cigarettes/d) | 20,0-24,9> 80%< 10%Normalnone | 25-29,9 or <20,070 – 80%10 – 20%Elevated5 -20  | > 30,0< 70%> 20%High> 20 | x 4 |
| **Neoadjuvant therapy** | yes |  |  | x 1 |

CHD = Coronary Heart Disease, PAD = Peripheral Arterial Disease